Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90.4M
-
Number of holders
-
425
-
Total 13F shares, excl. options
-
42.9M
-
Shares change
-
+2M
-
Total reported value, excl. options
-
$3.25B
-
Value change
-
+$73M
-
Put/Call ratio
-
1
-
Number of buys
-
195
-
Number of sells
-
-218
-
Price
-
$75.78
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2021
555 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2021.
CRISPR Therapeutics AG - Common Stock (CRSP) has 425 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.9M shares
of 90.4M outstanding shares and own 47.42% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (9.09M shares), Nikko Asset Management Americas, Inc. (4.32M shares), Capital International Investors (3.59M shares), NEA Management Company, LLC (1.59M shares), LOOMIS SAYLES & CO L P (1.32M shares), BlackRock Inc. (1.27M shares), CREDIT SUISSE AG/ (1.09M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.09M shares), EcoR1 Capital, LLC (1.08M shares), and Bellevue Group AG (975K shares).
This table shows the top 425 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.